Your Messages Inbox
Your Article Summary
See Latest ArticlesAstellas to Nominate Two Directors to CV Therapeutics Board
PharmExec, 03/12/09
The hostilities continue between Astellas and its unwilling acquisition target, CV Therapeutics. Astellas announced Monday that its subsidiary, Astellas US Holding Inc., will nominate two directors for election to the board of directors of CV Therapeutics, and file a stockholder proposal to remove the four remaining directors. The vote will take place at the CVT 2009 annual meeting. The final date has not yet been set, although last year’s event was held in late May. To take office, Astellas' nominees must receive a plurality of stockholder votes cast. CVT’s certificate of incorporation then allows for the remaining directors to be removed without cause by holders of two-thirds of the outstanding shares. Astellas' nominees would replace CVT's chairman and CEO Louis G.
Today in Execs on the Move...keeping you current
Receive free subspecialty "5-minute updates" via email
The Joint Commission Names Charles R. Buck to Board of Commissioners, Connie S. March to Represent Long Term Care Field
Joint Commission news, 12/07/09
Thomas H. Silberg to Retire as President and CEO of APP Pharmaceuticals, John Ducker Named as Successor
American Pharmaceutical Partners, 12/03/09
Cardinal Health names Carrie Cox to board of directors
Cardinal Health, 12/03/09
Article Search
Sponsor